August 1, 2017
Onxeo divests two non-core products in oral pathologies to Vectans Pharma
Onxeo has sold of two products Sitavig and Loramyc to Vectans Pharma, a private pharmaceutical company which develops and markets innovative therapeutics in oral pathologies.